Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.7.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Current assets:    
Cash $ 8,088 $ 23,014
Accounts receivable - trade 175 484
Accounts receivable - unbilled 0 122
Work in process 26 22
Prepaid expenses and other current assets 283 264
Total Current Assets 8,572 23,906
Fixed assets, net of accumulated depreciation 25,589 25,574
Intangible assets, net of accumulated amortization 1,823 2,092
Security deposit 26 28
Total Assets 36,010 51,600
Current liabilities:    
Accounts payable (related party of $87 and $200 as of June 30, 2017 and 2016, respectively) 749 1,177
Accrued expenses (related party of $650 and $623 as of June 30, 2017 and 2016, respectively) 924 920
Capital lease obligation - current portion 183 170
Deferred revenue 157 24
Total Current Liabilities 2,013 2,291
Capital lease obligation - net of current portion 25,082 25,265
Total Liabilities 27,095 27,556
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:    
Preferred stock - no par value; 1,000,000 shares authorized; 1 and 0 shares issued and outstanding as of June 30, 2017 and 2016, respectively 0 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,118,510 and 89,109,410 shares issued and outstanding as of June 30, 2017 and 2016, respectively 89 89
Additional paid-in capital 80,977 67,468
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (72,123) (57,591)
Total iBio, Inc. Stockholders’ Equity 8,914 9,937
Noncontrolling interest 1 14,107
Total Equity 8,915 24,044
Total Liabilities and Equity $ 36,010 $ 51,600